Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Net Cash Flow (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Net Cash Flow for 16 consecutive years, with $3.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 1215.43% to $3.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $23.6 million, a 2318.05% increase, with the full-year FY2024 number at -$23.5 million, down 182.86% from a year prior.
  • Net Cash Flow was $3.8 million for Q3 2025 at Gyre Therapeutics, down from $21.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $52.7 million in Q1 2021 to a low of -$52.3 million in Q3 2022.
  • A 5-year average of $2.5 million and a median of -$3.7 million in 2024 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: crashed 372.39% in 2021, then soared 1215.43% in 2025.
  • Gyre Therapeutics' Net Cash Flow stood at -$14.8 million in 2021, then soared by 385.95% to $42.3 million in 2022, then crashed by 56.08% to $18.6 million in 2023, then crashed by 125.6% to -$4.8 million in 2024, then surged by 178.94% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Net Cash Flow are $3.8 million (Q3 2025), $21.4 million (Q2 2025), and $3.2 million (Q1 2025).